Saluda Medical draws $25M debt tranche as it scales pain-relief device
What's the deal? Saluda Medical (ASX:SLD) has drawn US$25 million from the second tranche of its credit facility with Perceptive Credit Holdings IV, the company confirmed on July 1, 2026.
The facility, first signed in March 2025, spans US$125 million across three tranches. Saluda drew the first US$75 million on signing.
Proceeds from the second tranche will fund general commercial and operating purposes.
Why now? The second tranche unlocked on June 30, 2026, after Saluda met certain conditions attached to the deal.
A third tranche of US$25 million stays available through December 31, 2026, subject to further conditions. It remains undrawn.
What could go wrong? Debt comes with strings. Saluda issued Perceptive a warrant to buy 88,000 shares at US$17.00 each — roughly 880,000 CDIs at about A$2.65 apiece.
That dilutes existing shareholders if exercised. And the final tranche hinges on hitting more milestones before the year-end deadline.
The signal: As a late-stage company, Saluda is leaning on debt to bankroll the commercial rollout of a device with clinical backing rather than returning to equity markets — a route that spares shareholders further dilution beyond the Perceptive warrants. It's a well-worn playbook for medtech firms scaling a proven product past the point of pivotal trial validation.
Read more: listcorp.com
Image credit: JD Hancock
